Spyre Therapeutics, Inc.
NASDAQSpyre Therapeutics heads into its May 8 earnings call in a charged position — the Street is racing to lift targets after strong Phase 2 data, while the CEO, CFO, and CMO all hit the sell button on the same day the stock traded above $70. The analyst rerate has been fast and broad. Citigroup raised its target to $97 from $64 on May 6, and Stifel went to $107 from $92 the same day…
Snapshot as of 7 May 2026
Spyre Therapeutics heads into its May 8 earnings call in a charged position — the Street is racing to lift targets after strong Phase 2 data, while the CEO, CFO, and CMO all hit the sell button on the same day the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SYRE — free to start on ORTEX.
Sign up for free →Open SYRE on ORTEX